Mobidiag will showcase its fast, reliable and cost-effective
molecular diagnostic solutions

ESPOO, Finland–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/ECCMID19?src=hash” target=”_blank”gt;#ECCMID19lt;/agt;–Mobidiag Ltd., a commercial stage molecular diagnostics company
addressing the spread of antimicrobial resistance, will be attending the
29th European Congress of Clinical Microbiology & Infectious Diseases
(ECCMID) in Amsterdam, the Netherlands, from 13-16 April 2019. Organised
by Europe’s leading society in clinical microbiology and infectious
diseases, the ECCMID annual meeting brings together leading experts from
around the world, including innovative commercial companies specializing
in diagnostics.

Mobidiag will be hosting an Exhibit Booth (#1.62, Hall 3) at ECCMID. The
Company will demonstrate its proprietary diagnostic solutions, Amplidiag^®
and Novodiag^® and showcase how these can be used to provide
fast, accurate and accessible solutions for the diagnosis of infectious
diseases and, particularly in antimicrobial resistance.

Mobidiag has made significant progress in recent months, including:

• Mobidiag
  Joint Venture with Autobio Diagnostics and €10m equity investment
  (17/12/18)
• Mobidiag
  Announces Release of Novodiag^® CarbaR+ test allowing rapid,
  cost-effective molecular testing for ‘superbacteria’ and associated
  drug resistance (19/01/19)
• Mobidiag
  signed multiple international agreements for distribution of its
  Amplidiag^® and Novodiag^® diagnostic solutions
  (25/02/19)

Mobidiag’s management, R&D and commercial & marketing teams will be
available to address any questions. If you would like to arrange a
meeting with the team, please contact the Company by email: sales@mobidiag.com.

About Mobidiag Ltd

Mobidiag is a commercial stage, fast growing molecular diagnostics
company whose affordable, widely applicable and robust technology makes
the power of molecular diagnostics available to address the spread of
antimicrobial resistance (AMR) by rapid detection of pathogens and their
potential resistance to antibiotics. Through its Amplidiag^®
and Novodiag^® solutions, Mobidiag offers a comprehensive
range of fast, reliable and cost-effective molecular diagnostic
solutions for the detection of infectious diseases to laboratories of
all sizes.

Mobidiag is headquartered in Espoo, Finland, with subsidiaries in
France, UK and Sweden. To learn more, visit www.mobidiag.com

Contacts

Mobidiag
Dorothee Allard, Marketing Communications Manager
+33
1 55 25 17 13
marketing@mobidiag.com

Consilium Strategic Communications
Chris Gardner, Matthew Neal,
Chris Welsh
T: +44 (0)203 709 5700
mobidiag@consilium-comms.com